SIPS 2018

DETAILLED PROGRAM OVERVIEW

Oxidative Stress: Can We Reduce Oxidative Stress in Various Diseases?
Haruhiko Inufasa¹;
¹GIFU UNIVERSITY, Osaka, Japan;
PAPER: 399/Electrochemistry/Invited (Oral)
SCHEDULED: 15:55/Tue./Copacabana B (150/1st)

ABSTRACT:
Reactive Oxygen Species (ROS) are closely related to various diseases or symptoms. Twendee X (TWX) is an antioxidant composition consisting of Vitamin C, L-Glutamine, L-Cystine or L-Cysteine, Riboflavin, Succinic acid, Fumaric acid, Coenzyme Q10, and Niacin. TWX was invented from the basic experiments of alcohol, glucose, and fat metabolisms (1-4). TWX strongly reduces ROS (Patent: WIPO WO2013/072441 A1, COMPOSITION FOR PROTECTION AGAINST CELL-DAMAGING EFFECTS). Lysozyme radiation experiments showed that antioxidant effects of TWX are 6-7 times higher than Vitamin C (Data from Dr. Helmut Durschschlarg, Regensburg Univ. Germany). Oxidative stress and mitochondrial expert ICDD (France) experiments using hepatic cancer cell line HepG2 showed TWX decreases 63% mitochondrial ROS and increases 147% mitochondrial SOD. ICDD confirmed that TWX is safe and has the strongest anti-ROS and protection effects from ROS. TWX was also shown to increase the Neogenesis nerve cell number of the hippocampal dentate gyrus in the 56 week-old mouse, which was increased to the same as the 6 week-old mouse. Mitochondrial metabolism of the mouse hippocampal dentate gyrus was activated by TWX administration according to metabolome analysis. The Japanese Association for Prevention Dementia started a double blind clinical trial from autumn 2017 for 400 patients with Mild Cognitive Impairment and stroke, to prove TWX prevention effects on Alzheimer's disease and Vascular dementia. TWX effects were monitored in various disease and symptoms. Monitoring questionnaires was conducted by I’s Corporation (Tokyo), who holds over 100,000 of internet monitoring members in Japan. TWX (13-15 mg/kg/day) was administered to those that suffered from the following disease or symptoms: chronic sinusitis (80 patients), atopic dermatitis (68 patients), asthma (44 patients), pollinosis (107 patients), fatigue (107 patients), etc. All data collected by the website was analyzed by I’s Corporation. A small clinical trial was also conducted for sleep apnea, hepatic disease, hyperthyroidism, diabetes, and stroke. All reports from I’s Corporation are listed on I’s Corporation home page (https://www.eyez.jp/case_reports). The effectiveness and partial effectiveness of TWX in these diseases' symptoms are as follows: chronic sinusitis 78%, atopic dermatitis 80%, asthma 95%, pollinosis 85%, fatigue 80%. Asthma attack numbers were significantly reduced from before TWX administration. All other diseases also showed positive effects. Diabetic peripheral neuropathy patients reported that symptoms disappeared within 8 weeks after start administration of TWX. TWX has strong potential to treat various disease and symptoms, and its ability to decrease asthma attacks without side effects has presented itself as a major benefit for asthma patients.